Blood testing companies report divergent earnings, Natera's loss exceeds expectations.

Natera reported a third-quarter loss of $0.42 per share, wider than the $0.29 expected, while revenue reached $794 million versus the $708 million consensus, and the blood-testing firm joined Guardant Health in raising full-year revenue guidance. Guardant posted a narrower-than-expected loss of $0.29 per share against a $0.31 estimate, with revenue of $361 million topping the $351 million forecast. The results contrast with rival Grail, whose Galleri cancer test has shown weak sales and disappointed investors. Veracyte also flagged soft prostate cancer test volumes, while lab tools maker 10x Genomics beat expectations with a $0.15 per share loss and $150.7 million in revenue. The diverging prints matter as investors gauge whether cancer-screening demand can sustain elevated growth expectations across the sector. Next, watch fourth-quarter volumes and uptake of Galleri and prostate tests for signs of whether the guidance raises hold.